Marchex, Inc. (MCHX) EPS Estimated At $-0.02; Halozyme Therapeutics, Inc. (HALO) Covered By 5 Bulls

January 14, 2018 - By Hazel Jackson

Analysts expect Marchex, Inc. (NASDAQ:MCHX) to report $-0.02 EPS on February, 15.They anticipate $0.07 EPS change or 77.78% from last quarter’s $-0.09 EPS. After having $-0.02 EPS previously, Marchex, Inc.’s analysts see 0.00% EPS growth. The stock decreased 1.78% or $0.06 during the last trading session, reaching $3.31. About 57,027 shares traded. Marchex, Inc. (NASDAQ:MCHX) has declined 8.92% since January 14, 2017 and is downtrending. It has underperformed by 25.62% the S&P500.

Among 8 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Halozyme Therapeutics had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Barclays Capital on Tuesday, September 22. The company was maintained on Friday, September 15 by Deutsche Bank. Piper Jaffray maintained the shares of HALO in report on Friday, September 16 with “Overweight” rating. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The company was maintained on Wednesday, August 9 by Piper Jaffray. The rating was maintained by Barclays Capital on Wednesday, February 24 with “Overweight”. The firm has “Buy” rating given on Wednesday, July 26 by Canaccord Genuity. The company was initiated on Friday, December 4 by Wells Fargo. Deutsche Bank initiated the shares of HALO in report on Thursday, November 3 with “Buy” rating. As per Friday, September 15, the company rating was maintained by BMO Capital Markets. See Halozyme Therapeutics, Inc. (NASDAQ:HALO) latest ratings:




22/11/2017 Broker: Barclays Capital Rating: Hold New Target: $19.0 Downgrade
08/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $17 New Target: $19 Maintain
08/11/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $15 New Target: $18 Maintain
14/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Maintain
15/09/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $14 New Target: $15 Maintain
15/09/2017 Broker: Deutsche Bank Rating: Buy New Target: $20.0 Maintain
09/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $20.0000 Maintain
26/07/2017 Broker: Canaccord Genuity Rating: Buy New Target: $16.0000 Maintain

Marchex, Inc. operates as a mobile advertising analytics company. The company has market cap of $144.55 million. The Company’s products include Marchex Call Analytics, an analytics technology platform that provides data and insights to measure the performance of mobile, online, and offline advertising for advertisers and small business resellers; and Marchex Search Analytics, a product for search marketers that drive phone calls from search campaigns, as well as attributes inbound phone calls made directly from paid search ads and landing pages to a keyword. It currently has negative earnings. The firm also provides Marchex Display and Video Analytics, a product for marketers that buy digital display advertising, as well as measures the influence that display advertising has on inbound phone calls; Marchex Social Analytics, a product for marketers that buy social media advertising; and Marchex Call Marketplace, a mobile advertising network for businesses that depend on inbound phone calls to drive sales, as well as offer advertisers ad placements across various mobile and online media sources to deliver qualified calls to their businesses.

Investors sentiment decreased to 0.92 in 2017 Q3. Its down 0.14, from 1.06 in 2017Q2. It is negative, as 9 investors sold Marchex, Inc. shares while 17 reduced holdings. 6 funds opened positions while 18 raised stakes. 20.74 million shares or 1.73% less from 21.10 million shares in 2017Q2 were reported. Ameriprise Fin stated it has 0% of its portfolio in Marchex, Inc. (NASDAQ:MCHX). Tower Rech Capital Ltd Llc (Trc) reported 0.01% of its portfolio in Marchex, Inc. (NASDAQ:MCHX). State Street invested in 0% or 15,512 shares. Geode Mgmt holds 164,240 shares or 0% of its portfolio. Synovus Fincl holds 174,710 shares or 0.01% of its portfolio. Roumell Asset Ltd Liability Co has 10.46% invested in Marchex, Inc. (NASDAQ:MCHX) for 1.44M shares. Millennium Mgmt Ltd Llc invested in 397,019 shares or 0% of the stock. Sei Invs Company has invested 0% of its portfolio in Marchex, Inc. (NASDAQ:MCHX). 23,101 are owned by Brandywine Inv Mgmt Ltd. Matarin Cap Mngmt Llc accumulated 37,225 shares or 0.01% of the stock. Segall Bryant & Hamill Ltd Liability Co holds 0.05% or 728,640 shares. Prescott Gp Management Limited Liability Com owns 4.30M shares or 2.71% of their US portfolio. Goldman Sachs Grp Inc accumulated 0% or 53,653 shares. Element Capital Ltd Liability Com, a New York-based fund reported 92,699 shares. Manufacturers Life Co The owns 377 shares.

Among 4 analysts covering Marchex (NASDAQ:MCHX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Marchex had 10 analyst reports since August 6, 2015 according to SRatingsIntel. Piper Jaffray maintained Marchex, Inc. (NASDAQ:MCHX) rating on Friday, August 28. Piper Jaffray has “Overweight” rating and $9 target. The stock of Marchex, Inc. (NASDAQ:MCHX) earned “Outperform” rating by RBC Capital Markets on Thursday, November 5. TH Capital initiated it with “Buy” rating and $6 target in Tuesday, December 22 report. The stock has “Neutral” rating by Roth Capital on Wednesday, August 10. The company was initiated on Tuesday, December 22 by Roth Capital. RBC Capital Markets maintained Marchex, Inc. (NASDAQ:MCHX) on Friday, February 19 with “Outperform” rating. The firm has “Overweight” rating by Piper Jaffray given on Friday, August 7.

The stock increased 1.50% or $0.3 during the last trading session, reaching $20.36. About 802,413 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since January 14, 2017 and is uptrending. It has outperformed by 28.19% the S&P500.

Investors sentiment decreased to 1.26 in Q3 2017. Its down 0.76, from 2.02 in 2017Q2. It dropped, as 14 investors sold Halozyme Therapeutics, Inc. shares while 44 reduced holdings. 18 funds opened positions while 55 raised stakes. 118.53 million shares or 0.58% less from 119.22 million shares in 2017Q2 were reported. Snyder Capital Ltd Partnership accumulated 2.14% or 2.47M shares. Geode Capital Mngmt Ltd Limited Liability Company reported 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). 22,000 are held by Sterling Global Strategies Lc. Third Security Llc has 17.59M shares. State Of New Jersey Common Pension Fund D has invested 0.02% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Chicago Equity Ptnrs Ltd Llc invested 0.11% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). The New York-based Orbimed Ltd Limited Liability Company has invested 0.06% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Trexquant Inv L P holds 0.06% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 12,915 shares. Segall Bryant Hamill Lc stated it has 13,400 shares. Janney Montgomery Scott Limited Liability Corporation stated it has 84,373 shares. Msd Lp holds 1.14% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 2.25M shares. Dupont Management Corp, Delaware-based fund reported 48,270 shares. Alliancebernstein L P has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Sg Americas Secs Ltd Company accumulated 28,081 shares or 0% of the stock. State Of Wisconsin Investment Board owns 80,000 shares or 0% of their US portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.